Senate committee hears bill to require fertility-preservation coverage for some cancer patients

The Nevada Senate Committee on Commerce and Labor on Monday heard Assembly Bill 428, which would require many public and private health plans — including Medicaid and insurance for state and local government employees — to cover medically necessary fertility-preservation procedures for insured people diagnosed with breast or ovarian cancer.

Assemblymember Tanya Flanagan, D-7, who sponsored the bill, told the committee she brought the proposal after her own cancer diagnoses and after speaking with other patients. “I am a three-time breast cancer survivor myself,” Flanagan said. She told the committee an urgent practical problem: patients often face treatment decisions within a short window and may lack coverage to preserve eggs or embryos prior to chemotherapy or radiation.

The bill text presented to the committee states that insurers must cover procedures or services deemed medically necessary to preserve fertility when the insured has been diagnosed with breast or ovarian cancer and the cancer or its expected treatment could directly or indirectly cause infertility. The draft also includes a religious exemption: an insurer affiliated with a religious organization may opt out if it provides written notice that it does not provide the coverage.

Flanagan cited national cost estimates for fertility preservation, saying the National Institutes of Health reports embryo preservation costs of about $10,000 to $15,000, with additional storage fees. She also summarized nationwide uptake: “There are about 18 states and the District of Columbia that have passed legislation” requiring some insurer coverage for fertility preservation in similar circumstances, and she said roughly 268,000 women are diagnosed with invasive breast cancer annually in the U.S., about 12 percent of whom are under age 45 — the sponsor used those figures to estimate the likely Nevada population affected as small but meaningful.

Senators on the committee asked how prescriptive the bill is about benefit design. Sen. Grama noted the bill references guidance from the American Society for Reproductive Medicine and the American Society of Clinical Oncology and asked whether the bill should specify the number of retrievals, the length of storage, or similar limits. Flanagan said the bill is intentionally flexible to allow plans and providers to structure benefits responsibly; she described discussions with the Department of Education (PED) and cost-conscious approaches such as limiting coverage to one opportunity per plan year or two opportunities within a 12-month period as examples committee staff and stakeholders could consider when drafting benefit rules.

A single witness, identified as Leo Penovias from the University of Nevada, Las Vegas, testified in support of AB 428. The committee reported no callers in opposition and no callers in neutral during the hearing. The committee closed the public hearing on AB 428 and noted that a work session on the measure would be held later "behind the bar" on the floor.

Supporters said the bill would fill a coverage gap for people who face immediate cancer treatment decisions; senators questioned how benefit limits and storage rules would be implemented and flagged the role of clinical guidelines in shaping coverage details.

A work session on the bill was announced to take place later in the legislative day.